Published in Gene Therapy Weekly, May 26th, 1997
"The significant finding in this study is that for the first time, an immune response against GD3 was observed in all patients vaccinated with our new preparation," reported Dr. Govindaswami Ragupathi during a press briefing.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.